PriceTargets.com logo

INVO Bioscience - INVO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.40 As of 04/19/2024 04:33 PM ET
▼ -0.12 (-7.89%)

This chart shows the closing price for INVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New INVO Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INVO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for INVO Bioscience in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.40.

This chart shows the closing price for INVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in INVO Bioscience. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/26/2022Maxim GroupLower Target$60.00Low
4/13/2022Roth CapitalDowngradeBuy ➝ Neutral$80.00 ➝ $40.00High
3/22/2022Colliers SecuritiesReiterated RatingBuyLow
1/19/2022Maxim GroupInitiated CoverageBuy$140.00High
8/18/2021Roth CapitalLower TargetBuy$115.00 ➝ $105.00Medium
12/29/2020Roth CapitalReiterated RatingBuyN/A
12/29/2020Roth CapitalInitiated CoverageBuyN/A
12/15/2020Colliers SecuritiesReiterated RatingBuyHigh
12/15/2020Colliers SecuritiesInitiated CoverageBuyMedium
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 6 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

INVO Bioscience logo
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. INVO Bioscience, Inc. was founded in 2007 and is based in Sarasota, Florida.
Read More

Today's Range

Now: $1.40
Low: $1.30
High: $1.47

50 Day Range

MA: $1.03
Low: $0.77
High: $1.82

52 Week Range

Now: $1.40
Low: $0.50
High: $10.50

Volume

1,290,037 shs

Average Volume

3,142,316 shs

Market Capitalization

$3.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of INVO Bioscience?

The following sell-side analysts have issued research reports on INVO Bioscience in the last twelve months:
View the latest analyst ratings for INVO.

What is the current price target for INVO Bioscience?

0 Wall Street analysts have set twelve-month price targets for INVO Bioscience in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for INVO Bioscience in the next year.
View the latest price targets for INVO.

What is the current consensus analyst rating for INVO Bioscience?

INVO Bioscience currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for INVO.

What other companies compete with INVO Bioscience?

Other companies that are similar to INVO Bioscience include Nemaura Medical, Bluejay Diagnostics, Quoin Pharmaceuticals, Dynatronics and Tenon Medical. Learn More about companies similar to INVO Bioscience.

How do I contact INVO Bioscience's investor relations team?

INVO Bioscience's physical mailing address is 5582 BROADCAST COURT, SARASOTA FL, 34240. The company's listed phone number is (978) 878-9505 and its investor relations email address is [email protected]. The official website for INVO Bioscience is www.invobioscience.com. Learn More about contacing INVO Bioscience investor relations.